Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President | 24.92M | -- | 1951 |
| Ms. Heather Rees CPA | Chief Financial Officer | 10.7M | -- | 1972 |
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR | -- | -- | -- |
| Mr. Michael Parks | Vice President of Investor & Public Relations | -- | -- | -- |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer | -- | -- | -- |
Atossa Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Corporate Governance
Upcoming Events
March 31, 2025 at 10:59 AM UTC - April 4, 2025 at 12:00 PM UTC
Atossa Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available